Insider buying last 90 days
No open-market insider purchases were filed for TGTX in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every TGTX insider filing, plotted on the chart in Gekko.Open TGTX in Gekko
NASDAQ: TGTX
TG Therapeutics (TGTX) Stock Analysis & Forecast
Sep 28 close
$56.19−1.24 (−2.2%)
Gekko Brief
AI summaryThis week's news for TG Therapeutics centers on a shareholder litigation investigation, with Kuehn Law, PLLC examining company officers and directors for potential self-dealing and breach of fiduciary duties. Separate coverage compared TGTX to peer Puma Biotechnology across dividends, analyst recommendations, earnings and valuation, while other pieces noted the company's Q2 2026 results, driven by BRIUMVI, and cited bullish technical signals alongside analyst upside projections.
TGTX closed at $56.19, down 2.2%, though the stock remains above both its 50-day average of $53.63 and 200-day average of $40.84, with the shorter average also above the longer one. The GekkoIndex reads 55.8, placing the stock in the Neutral zone. Price sits 6.4% below Gekko Fair Value of $60.05. The 52-week range spans $26.76 to $59.30, and one-year return stands at 62.2%.
The next earnings date falls on 2 November 2026, before the open, 34 days out and beyond a typical 20-day holding window; the prior report on 3 August 2026 showed EPS of $0.05 against a $0.41 estimate, with a -6.3% reaction. Over the last 30 days, one unusual options signal appeared, with put premium of $292,880 and no call premium recorded. Five-year seasonality for this calendar stretch has averaged -7.6% over the next 20 trading days, without a single positive occurrence. Consensus among 6 analysts stands at 5 buy, 0 hold, 1 sell, with a target of $69.71.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
TG Therapeutics price vs fair value
Close $56.19200-day averageGekko Fair Value $60.05
TG Therapeutics quick facts
- Market cap
- $8.60B
- P/E ratio
- 20.5
- Forward P/E
- 25.9
- EPS, TTM
- $2.81
- Revenue, TTM
- $799.5M
- Profit margin
- 55.2%
- Dividend yield
- —
- Beta
- 1.66
- Volume
- 1.43M avg 1.84M
- 1-year return
- +62.2%
- Typical daily move
- ±4.2%
- Typical 20-day move
- ±13.9%
- 50-day average
- $53.63
- 200-day average
- $40.84
- Next earnings
- Nov 2 before open
- Shares outstanding
- 153.1M
TG Therapeutics swing-trade checklist
TG Therapeutics scores 3 supportive, 1 mixed and 2 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed2 headwinds
- Trendsupportive
Above 50 and 200-day
Close $56.19 is above the 50-day ($53.63) and 200-day ($40.84) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
55.8, Neutral
Reading 55.8 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
6.4% below
Price is 6.4% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyheadwind
Leans bearish
Last 30 days: 1 unusual options signal.
See smart money - Earnings risksupportive
Reports in 34 days
Next report Nov 2, 2026, 34 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−7.6% on average
From this point in the calendar, the next 20 trading days averaged −7.6% over 5 years, rising in 0 of them.
See seasonality
A description of current data, not a recommendation. How this page works
TG Therapeutics stock chart and price history
TG Therapeutics closed at $56.19 on Sep 28, 2026, +62.2% over the past year, inside a 52-week range of $26.76 to $59.30.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +0.8%
- 3 months
- +0.8%
- 6 months
- +77.0%
- 1 year
- +62.2%
The full TGTX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open TGTX in Gekko
Follow TG Therapeutics through every session
Put TGTX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track TGTX in GekkoFree for 7 days. No credit card required.
About TG Therapeutics
TG Therapeutics is a biopharmaceutical company that has reached the commercial stage, working to acquire, develop and bring to market treatments for B-cell related cancers and autoimmune conditions. It is known for its work on Ublituximab, a glycoengineered monoclonal antibody studied for B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia and relapsing forms of multiple sclerosis, alongside other pipeline candidates aimed at similar patient populations.
Its broader portfolio includes Umbralisib, an oral compound targeting PI3K-delta and CK1-epsilon for use in CLL and lymphoma, Cosibelimab, an antibody aimed at PD-L1, TG-1701, an oral BTK inhibitor, and TG-1801, a bispecific antibody directed at CD47 and CD19. The company also holds licensed preclinical programs covering BET, IRAK4 and GITR, and it works with outside partners on research and development, including Checkpoint Therapeutics, Jiangsu Hengrui Medicine, Novimmune, Ligand Pharmaceuticals, Jubilant Biosys, LFB Biotechnologies, GTC Biotherapeutics, LFB/GTC LLC, Ildong Pharmaceutical and Rhizen Pharmaceuticals.
TG Therapeutics is based in New York City and was established in 1993. Its shares are listed on the NASDAQ under the ticker TGTX.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- tgtherapeutics.com
TG Therapeutics GekkoIndex: the smart money zone
TG Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 55.8, in the Neutral zone, up 4.3 points over five sessions.
55.8Neutral
Up 4.3 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 17 | +1.6% | +11.6% | ||
| Accumulation | 195 | +3.2% | +9.1% | ||
| Neutral (current zone) | 397 | +0.6% | +3.8% | ||
| Distribution | 60 | −0.2% | −1.9% | ||
| Selling | 3 | Too few readings yet | |||
Average TGTX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the TGTX price, zone by zone.Track TGTX in Gekko
Is TG Therapeutics stock overvalued? Gekko Fair Value
TG Therapeutics trades 6.4% below Gekko Fair Value of $60.05, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what TG Therapeutics shares are worth, recalculated every trading day.
$60.05
Gekko Fair Value, Sep 26, 2026
6.4% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open TGTX in Gekko
TG Therapeutics insider and Congress trading
No open-market insider purchases were filed for TG Therapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in TGTX were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for TGTX, plotted on the chart in Gekko.Open TGTX in Gekko
Buybacks
TG Therapeutics has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $99.99M
- As a share of market cap
- 1.16%
From company filings.
Unusual options activity last 30 days
1signal, 0% of the flagged premium in calls.
Latest: Bearish flow on Sep 17, $293K in unusual premium.
Hedge funds and billionaires quarter ended Mar 31
1of the funds Gekko tracks holds TGTX.
0added0opened1trimmed0sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko
TG Therapeutics earnings: next date and track record
TG Therapeutics reports on Nov 2, 2026, before the open (34 days away), and beat the EPS estimate in 2 of its last 8 reports.
Next earnings report
Nov 2, 2026
Expected before the open, 34 days away
- EPS estimate
- $0.36
- Revenue estimate
- $247.1M
2 of 8reports beat the EPS estimate
±11.3%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 3, 2026 AI summary
- What they said
- TGTX reported strong Q2 2026 results, exceeding guidance with BRIUMVI approaching a $1 billion annualized revenue run rate. Positive Phase III ENHANCE study results showed a simplified single-dose 600mg initiation schedule. Subcutaneous ublituximab Phase I bioavailability data was positive, with Phase III top-line results expected year-end or early next year. Management is targeting the #1 anti-CD20 therapy position in relapsing MS.
- Guidance
- Management expects the single-infusion initiation schedule to be available by mid-next year pending approval. Subcutaneous BRIUMVI Phase III top-line results anticipated year-end 2026 or early 2027, potentially doubling the addressable market by entering the self-administered segment.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 3, 2026 | $0.05 est $0.41 | $240.3M est $229.8M | −6.3% |
| May 6, 2026 | $0.18 est $0.28 | $204.9M est $200.3M | +19.2% |
| Feb 26, 2026 | $0.14 est $0.33 | $192.6M est $191.8M | +1.4% |
| Nov 3, 2025 | $2.43 est $0.24 | $161.7M est $193.8M | −2.8% |
| Aug 4, 2025 | $0.17 est $0.29 | $141.1M est $146.3M | −18.9% |
| May 5, 2025 | $0.03 est $0.17 | $120.9M est $134.2M | −19.8% |
| Mar 3, 2025 | $0.15 est $0.09 | $108.2M est $108.8M | +18.4% |
| Nov 4, 2024 | $0.02 est $0.03 | $83.88M est $98.79M | −3.9% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
TG Therapeutics stock forecast and analyst price targets
Analysts’ average 12-month price target for TG Therapeutics is $69.71, +24.1% from the last close, from 6 firms rating the stock in the last 90 days.
$69.71consensus 12-month target, +24.1% from the last close
Now $56.19Avg $69.71
Low $21High $86
Each firm’s latest rating in the last 90 days: 6 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 21 | H.C. Wainwright | $78 | +38.8% |
| Sep 2 | B. Riley Securities | $86 | +53.1% |
| Sep 1 | H.C. Wainwright | $78 | +38.8% |
| Aug 5 | Bank of America Securities | $21 | −62.6% |
| Aug 4 | H.C. Wainwright | $78 | +38.8% |
+3.8%average 20-day move after past Neutral readings
−7.6%average move over the next 20 trading days in the last 5 years
±4.2%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
TG Therapeutics seasonality: the next 20 trading days
Over the next 20 trading days from Sep 26, TG Therapeutics averaged −7.6% across the last 5 years, rising in 0 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −1.8% | 2 of 5 |
| Next 10 trading days | −8.1% | 0 of 5 |
| Next 15 trading days | −3.5% | 2 of 5 |
| Next 20 trading days | −7.6% | 0 of 5 |
| Next 30 trading days | +6.6% | 4 of 5 |
For scale, TGTX’s typical 20-trading-day move in either direction is about 13.9%.
TG Therapeutics market cap and key statistics
TG Therapeutics’s market cap is $8.60B, with a P/E ratio of 20.5 and revenue of $799.5M over the last twelve months.
Valuation
- Market cap
- $8.60B
- P/E ratio
- 20.5
- Forward P/E
- 25.9
- EPS, TTM
- $2.81
- Gekko Fair Value
- $60.05
Trading
- Volume
- 1.43M
- Avg volume, 20 days
- 1.84M
- 52-week high
- $59.30
- 52-week low
- $26.76
- Shares outstanding
- 153.1M
Financials
- Revenue, TTM
- $799.5M
- Profit margin
- 55.2%
- Return on equity
- 100.3%
- Quarterly earnings growth, YoY
- −70.6%
Risk and income
- Beta
- 1.66
- Typical daily move
- ±4.2%
- Typical 20-day move
- ±13.9%
TG Therapeutics stock news this week
Coverage of TG Therapeutics this week reads neutral: 1 positive, 1 neutral and 1 negative headlines.
- Investigation launched into TG Therapeutics' of...Pluang, Sep 28
- Kuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law FirmPRNewsWire, Sep 28
- Comparing TG Therapeutics (NASDAQ:TGTX) and Puma Biotechnology (NASDAQ:PBYI)Defense World, Sep 26
- TG Therapeutics, Inc. (TGTX) Options Chain - Yahoo FinanceYahoo! Finance Canada, Sep 25
- TG Therapeutics Inc (TGTX) Stock Price Today: $56.12Pluang, Sep 24
TG Therapeutics peers
TG Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 17.9% above |
| JNJJohnson & Johnson | Neutral | 0.5% above |
| ABBVAbbVie | Neutral | 23.3% above |
| MRKMerck | Neutral | 4.2% below |
| AZNAstraZeneca | Neutral | 39.9% below |
| PFEPfizer | Neutral | 4.0% below |
A peer links to its own page where one exists.
TG Therapeutics stock FAQ
What is TG Therapeutics’s market cap?
TG Therapeutics’s market cap is $8.60B at the Sep 28, 2026 close of $56.19, with 153.1M shares outstanding. The shares trade on a P/E ratio of 20.5.
What is the TG Therapeutics stock forecast?
The consensus analyst 12-month price target for TG Therapeutics is $69.71, +24.1% from the last close. Of the 6 firms that rated the stock in the last 90 days, 5 rate it a buy, 0 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.
Is TG Therapeutics stock overvalued or undervalued?
On Gekko’s estimate TG Therapeutics is undervalued: the Sep 28, 2026 close of $56.19 is 6.4% below Gekko Fair Value of $60.05. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does TG Therapeutics report earnings next?
TG Therapeutics is expected to report on Nov 2, 2026, before the market opens (34 days away). Analysts expect earnings of $0.36 per share on revenue of $247.1M. TG Therapeutics beat the earnings estimate in 2 of its last 8 reports, moving 11.3% on average across the report.
What is TG Therapeutics’s 52-week high and low?
TG Therapeutics’s 52-week high is $59.30 and its 52-week low is $26.76; it closed at $56.19 on Sep 28, 2026, +62.2% over the past year.
Is TG Therapeutics stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 6 items with data read as supportive (trend, fair value and earnings risk), 1 as mixed (gekkoindex) and 2 as headwinds (smart money and seasonality). The checklist is a description of current data, not a recommendation.
Is there unusual options activity in TG Therapeutics?
Gekko flagged 1 unusual options signal in TG Therapeutics over the last 30 days, with $0 of flagged premium in calls and $293K in puts. The latest, bearish flow, was on Sep 17, 2026 with $293K in unusual premium. The signal-by-signal table is in Gekko.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See TG Therapeutics the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.